Hemogenyx Pharmaceuticals PLC Research Collaboration with Rockefeller University
08 May 2018 - 4:01PM
RNS Non-Regulatory
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
08 May 2018
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Research Collaboration with Rockefeller University
Collaboration targeting potential new treatments for Lupus using
Hemogenyx's humanized mice
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology
company developing novel therapies to transform bone marrow, or
blood stem cell, transplantation for the treatment of blood
diseases, announces that it has entered into a collaboration
agreement with The Rockefeller University ("Rockefeller"), one of
the world's foremost research institutions, with 82 labs dedicated
to basic and translational bioscience and strong commitment to
using the power of basic science to further the development of new
medicines and reduce human suffering. The collaboration calls for
scientists at Rockefeller to use Hemogenyx's new type of humanized
mice for autoimmune disease modelling in an effort to develop new
treatments for autoimmune diseases - specifically Lupus.
Under the agreement, the collaborative work will be co-led by
investigators at Hemogenyx and Rockefeller. Professor Alexander
Tarakhovsky, a member of Hemogenyx's Scientific Advisory Board and
Head of Rockefeller's Laboratory of Immune Cell Epigenetics and
Signaling, will act as the principal investigator for Rockefeller.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx, will act
as the principal investigator for Hemogenyx. The Directors of
Hemogenyx are confident that the collaboration does not require
forms of funding that would be dilutive to Hemogenyx
shareholders.
Dr. Sandler commented: "This agreement with Rockefeller has the
potential to extend our product candidate opportunities into a new
and exciting area, and we would fully expect to see the work funded
through future non-dilutive grant funding. Shareholders can now
also see the potential for the use of our technology beyond our
current bone marrow transplantation focus to treat debilitating and
otherwise incurable autoimmune diseases such as Lupus."
Lupus is a devastating and life-changing autoimmune disease in
which the body's immune system becomes hyperactive and attacks
normal, healthy tissues, resulting in symptoms such as
inflammation, swelling, and damage to joints, skin, kidneys, blood,
the heart, and lungs. The Lupus Foundation of America estimates
that 1.5 million Americans, and at least five million people
worldwide, have a form of Lupus. Lupus currently has no cure and
strikes mostly women of childbearing age. Most people with Lupus
develop the disease between the ages of 15-44.
The first stage of the development work will create a mouse
model using novel proprietary methods of mice humanization
developed by Hemogenyx. By using blood stem cells from subgroups of
patients with the early onset of Lupus, the project hopes to create
mice that emulate the human symptoms of Lupus. The second stage
will then focus on the development of multi-specific antibodies and
cell therapies to treat the disease in these mice.
Added Dr. Sandler: "The attractiveness of our new type of
humanized mice to major biotechnology companies and leading
research institutes will give us further opportunities to
collaborate on other disease models and specific drug
development."
On 26 February 2018, the Company confirmed the filing of a
provisional patent application relating to its development of a new
type of humanized mice with a chimeric mouse-human blood
system.
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer Via Walbrook PR
& Co-Founder
Sir Marc Feldmann, Executive Chairman
Optiva Securities Ltd Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey
Walbrook PR (UK Media & Investor Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Relations)
Paul McManus Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or lowell@lowellgoodman.net
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned U.S. operating
subsidiary, HemoGenyx LLC, located in its state-of-the-art research
facility in Brooklyn, New York. HemoGenyx is a preclinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapies and treatments for blood
diseases such as leukemia and lymphoma. The company's leading
technologies aim to change the way in which bone
marrow/hematopoietic stem cell (BM/HSC) transplants are performed
and improve their efficacy. HemoGenyx's two distinct and
complementary products include an immunotherapy product for patient
conditioning-the CDX bi-specific antibody-and a cell therapy
product for BM/HSC transplantation-the HuPHEC. Each of these
products holds the potential to revolutionize the way BM/HSC
transplants are being performed, offering solutions that mitigate
the dangers and limitations associated with the current standard of
care. For more information, visit www.hemogenyx.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAARMITMBMMBPP
(END) Dow Jones Newswires
May 08, 2018 02:01 ET (06:01 GMT)
Silver Falcon (LSE:SILF)
Historical Stock Chart
From Apr 2024 to May 2024
Silver Falcon (LSE:SILF)
Historical Stock Chart
From May 2023 to May 2024